Please login to the form below

Not currently logged in
Email:
Password:

Bicycle Therapeutics appoints Lee Kalowski

He joins the biotech from Tokai Pharmaceuticals

Lee KalowskiBiotechnology group Bicycle Therapeutics has appointed Lee Kalowski as chief financial officer at a time when the company explores a new class of therapeutics based on its proprietary bicyclic peptide product platform.

Prior to joining Bicycle, Kalowski served as the chief financial officer of Tokia Pharmaceuticals, where he helped lead the company’s $105m initial public offering in 2014.

He said: “Bicycle has pioneered a revolutionary platform that has generated a new class of drugs designed to target diseases more effectively.

“I am trilled to be joining the company as the pipeline continues to expand and as the company transitions into a clinical-stage biotech.”

Kalowski has also served Credit Suisse as its vice president, global biotechnology equity research and he has also worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson.

Kevin Lee, chief executive officer of Bicycle Therapeutics, said: “We are delighted to welcome Lee to the Bicycle team at this exciting time for our company.

“He brings a wealh of experience working with biotech companies at all stages of their evolution, both as a wall street research analyst and as a public company CFO, and his insights will prove invaluable as we continue to grow our business, expand our pipeline and move our lead candidate, BT1718, into clinical development.”

9th August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics